Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of tivantinib in treating younger
patients with solid tumors that have returned after a period of improvement or have not
responded to treatment. Tivantinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.